<DOC>
	<DOCNO>NCT00573690</DOCNO>
	<brief_summary>RATIONALE : Sorafenib pemetrexed may stop growth tumor cell block enzymes need cell growth . Sorafenib may also stop growth tumor cell block blood flow tumor . Drugs use chemotherapy , cisplatin , etoposide , carboplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving sorafenib together cisplatin etoposide carboplatin pemetrexed may kill tumor cell . PURPOSE : This phase I trial study side effect best dose sorafenib give together cisplatin etoposide carboplatin pemetrexed treat patient metastatic solid tumor .</brief_summary>
	<brief_title>Sorafenib Combined With Cisplatin Etoposide Carboplatin Pemetrexed Treating Patients With Metastatic Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine recommended phase II dose maximum tolerate dose sorafenib tosylate administer combination cisplatin etoposide carboplatin pemetrexed disodium patient metastatic solid tumor . Secondary - To characterize toxicity regimens patient . - To evaluate efficacy regimens patient , measure RECIST criterion tumor marker , applicable ( e.g. , PSA , CA-125 ) . - To determine pharmacokinetics sorafenib tosylate administer combination etoposide patient ( sample longer collect study longer perform 1/8/09 ) . OUTLINE : Patients assign 1 2 treatment group . - Group 1 : Patients receive cisplatin IV 1 hour day 2 course 1 2 day 1 subsequent course ; etoposide IV 30 minute day 1-3 ; oral sorafenib tosylate twice daily day 1-21 . Treatment repeat every 21 day absence unacceptable toxicity disease progression . - Group 2 : Patients receive carboplatin IV 30 minute pemetrexed disodium IV 10 minute day 1 . Patients also receive sorafenib tosylate group 1 . Treatment repeat every 21 day absence unacceptable toxicity disease progression . Patients group 1 undergo blood sample collection day 1 course 1 2 pharmacokinetic study ( sample longer collect study longer perform 1/8/09 ) . After finish treatment , patient follow 30 day .</detailed_description>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm metastatic solid tumor Disease progress least one standard therapy OR disease standard therapy No squamous cell carcinoma lung Asymptomatic brain metastasis allow provide follow criterion meet : Brain metastasis treat ≥ 6 month ago Brain metastasis clinically stable without steroid treatment 1 week No clinically relevant pleural effusion ascites control drainage ( group 2 ) PATIENT CHARACTERISTICS : ECOG performance status 01 Hemoglobin ≥ 9.0 g/dL ANC ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) ALT AST ≤ 2.5 time ULN INR &lt; 1.5 PT/PTT normal Creatinine clearance ≥ 45 mL/min Negative serum pregnancy test Fertile patient must use effective contraception least 2 week completion study treatment No New York Heart Association class III IV congestive heart failure No unstable angina ( anginal symptom rest ) new onset angina ( within past 3 month ) No myocardial infarction within past 6 month No cardiac ventricular arrhythmia require antiarrhythmic therapy No uncontrolled hypertension , define systolic blood pressure &gt; 150 mm Hg diastolic blood pressure &gt; 90 mm Hg , despite optimal medical management No known severe hypersensitivity sorafenib tosylate excipients , etoposide , pemetrexed disodium , cisplatin , carboplatin No known HIV infection No chronic hepatitis B C No active clinically serious infection &gt; CTCAE grade 2 No thrombotic embolic event , cerebrovascular accident transient ischemic attack , within past 6 month No pulmonary hemorrhage bleed event ≥ CTCAE grade 2 within past 4 week No hemorrhage bleed event ≥ CTCAE grade 3 within past 4 week No serious nonhealing wound , ulcer , bone fracture No evidence history bleed diathesis coagulopathy No condition impair patient 's ability swallow whole pill No malabsorption problem , uncontrolled inflammatory bowel disease , gastrointestinal disorder cause ≥ 5 bowel movement 24hour period No significant traumatic injury within past 4 week Able take vitamin B12 supplementation folic acid ( group 2 ) PRIOR CONCURRENT THERAPY : More 4 week since prior major surgery open biopsy No 3 prior cytotoxic therapy metastatic disease No concurrent St. John 's wort rifampin No nonsteroidal antiinflammatory drug ( NSAIDs ) 2 day ( 5 day longacting NSAIDs ) , , 2 day pemetrexed disodium administration ( group 2 ) Concurrent anticoagulation treatment warfarin heparin allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>